Evidence map›Paper›PMID 37299685›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Tailoring Magnetite-Nanoparticle-Based Nanocarriers for Gene Delivery: Exploiting CRISPRa Potential in Reducing Conditions.

David Arango, Javier Cifuentes, Paola Ruiz Puentes, Tatiana Beltran, Amaury Bittar, Camila Ocasión, Carolina Muñoz-Camargo, Natasha I Bloch, Luis H Reyes, Juan C Cruz

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Assessment of CRISPRa-mediatedFrontiers in bioengineering and biotechnology · 2024
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David ArangoDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.
Javier CifuentesDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0003-0916-3909
Paola Ruiz PuentesDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0003-4352-7999
Tatiana BeltranDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.
Amaury BittarDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.
Camila OcasiónDepartment of Chemical and Food Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.
Carolina Muñoz-CamargoDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0001-6238-9021
Natasha I BlochDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0002-4769-1027
Luis H ReyesDepartment of Chemical and Food Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0001-7251-5298
Juan C CruzDepartment of Biomedical Engineering, Universidad de Los Andes, Bogotá 111711, Colombia.ORCID 0000-0002-7790-7546
Universidad de Los Andes · CO

Funding

Minciencias 932-2019
6 · The paper itself

Abstract

Gene delivery has emerged as a promising alternative to conventional treatment approaches, allowing for the manipulation of gene expression through gene insertion, deletion, or alteration. However, the susceptibility of gene delivery components to degradation and challenges associated with cell penetration necessitate the use of delivery vehicles for effective functional gene delivery. Nanostructured vehicles, such as iron oxide nanoparticles (IONs) including magnetite nanoparticles (MNPs), have demonstrated significant potential for gene delivery applications due to their chemical versatility, biocompatibility, and strong magnetization. In this study, we developed an ION-based delivery vehicle capable of releasing linearized nucleic acids (tDNA) under reducing conditions in various cell cultures. As a proof of concept, we immobilized a CRISPR activation (CRISPRa) sequence to overexpress the

Indexed as

cell deliveryCRISPRadisulfide bondgene deliverymagnetite nanoparticlesnanoconjugatespink1

Identifiers

PMID37299685
PMCPMC10254418
OpenAlexW4379057118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.